Factors acting at the tumour–stroma interface include growth factors and their receptors, including TGFβ, in addition to ECM-related molecules (collagens, fibronectin, integrins), as well as oncogenic pathways (Ras, Src), all of which appear to be critically involved in EMT. The gene discussed is SRC; the disease is neoplasm.